High-dose melphalan with stem-cell transplantation is believed to be the most effective
treatment for systemic light-chain (AL) amyloidosis, but many patients are ineligible because …

Monoclonal immunoglobulin light chain amyloidosis (AL) is the commonest systemic type
with an age adjusted incidence of 5.1-12.8 per million patient years. 1 Treatment comprises …

High-dose melphalan with stem-cell transplantation is believed to be the most effective
treatment for systemic light-chain (AL) amyloidosis, but many patients are ineligible because …

Systemic light-chain amyloidosis (AL) is the most common systemic type with an age-
adjusted incidence of 5.1 to 12.8 per million patient years. 1 Treatment comprises …

Monoclonal immunoglobulin light chain amyloidosis (AL) is the commonest systemic type
with an age adjusted incidence of 5.1-12.8 per million patient years. 1 Treatment comprises …

抄録< jats: title> Abstract</jats: title>< jats: p> High-dose melphalan with stem-cell
transplantation is believed to be the most effective treatment for systemic light-chain (AL) …

High-dose melphalan with stem-cell transplantation is believed to be the most effective
treatment for systemic light-chain (AL) amyloidosis, but many patients are ineligible because …

High-dose melphalan with stem-cell transplantation is believed to be the most effective
treatment for systemic light-chain (AL) amyloidosis, but many patients are ineligible because …

High-dose melphalan with stem-cell transplantation is believed to be the most effective
treatment for systemic light-chain (AL) amyloidosis, but many patients are ineligible because …

Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in
systemic AL amyloidosis | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …